1. Introduction {#sec1-pharmaceuticals-12-00120}
===============

Iron deficiency is the most common type of malnutrition in humans \[[@B1-pharmaceuticals-12-00120],[@B2-pharmaceuticals-12-00120],[@B3-pharmaceuticals-12-00120],[@B4-pharmaceuticals-12-00120]\]. Iron deficiency occurs due to an inadequate intake, excess loss, or increased need, and gradually leads to insufficient functions of many organs, including the bone marrow, and as a consequence, iron deficiency leads to iron deficiency anemia \[[@B5-pharmaceuticals-12-00120],[@B6-pharmaceuticals-12-00120],[@B7-pharmaceuticals-12-00120]\]. According to the WHO, anemia affects 1.8 billion people worldwide, equivalent to approximately 25% of the world's population. Among this group, approximately 0.5 billion are women of a reproductive age, and in developing countries, the incidence of anemia is even higher and varies during pregnancy from 35% to 56% for Africa, 37% to 75% in Asia, and 37% to 52% in Latin America.

Women of a reproductive age are particularly at risk for developing iron deficiency due to menstrual bleeding and pregnancy. The prevalence of iron deficiency anemia in pregnant women is high, even in industrialized countries with well-established iron supplementation policies, e.g., in Denmark, where iron deficiency with anemia affects roughly 12% of pregnant women. The state of pregnancy greatly increases the demand of iron used in foetal organogenesis and growth. The pregnant body prioritizes the fetal iron supply over the maternal utilization up until a threshold of the maternal iron stores being adequate, with a maternal plasma ferritin concentration of approximately 14 µg/L \[[@B8-pharmaceuticals-12-00120]\]. When the maternal iron stores exceed this threshold, the placenta actively transports iron into the fetal circulation to ensure adequate iron supply to the fetus \[[@B9-pharmaceuticals-12-00120]\].

Iron deficiency can adversely affect brain development in fetuses and infants. Whereas most knowledge on the fetal needs for iron during pregnancy has been obtained within hematological, nephrology, and gastrointestinal disciplines, the impact on the fetal brain of maternal iron deficiency during pregnancy remains quite understudied. A higher turnover of iron in the developing brain \[[@B10-pharmaceuticals-12-00120]\], in addition to the widespread expression of iron-containing proteins, nonetheless dictate the importance of iron for the developing brain \[[@B11-pharmaceuticals-12-00120],[@B12-pharmaceuticals-12-00120],[@B13-pharmaceuticals-12-00120],[@B14-pharmaceuticals-12-00120]\]. This is particularly underscored by the profound expression of transferrin receptor 1 by dividing neuroprogenitor cells \[[@B15-pharmaceuticals-12-00120],[@B16-pharmaceuticals-12-00120]\] and signifies that cells of the developing brain with respect to their need for iron share a range of common conditions with precursor cells participating in bone marrow erythropoiesis and the formation of duodenal enterocytes of the fully developed organism. This review aims to summarize the current evidence on the significance of iron for the developing brain, how iron deficiency may impair functioning of the central nervous system (CNS) in the human brain and brains of experimental animals, and which therapeutic advances available can prevent damage to the developing CNS.

1.1. Transport of Iron into the Brain {#sec1dot1-pharmaceuticals-12-00120}
-------------------------------------

The brain acquires iron during life in a privileged manner in that its capillary endothelial cells are the only endothelial cells of the entire body that express transferrin receptors \[[@B17-pharmaceuticals-12-00120]\]. Iron circulates in blood exclusively bound to transferrin, unless pathological conditions like hemochromatosis occurs, which will result in the presence of low-molecular-weight forms of non-transferrin bound iron. The brain capillary endothelial cells form the blood--brain barrier (BBB) that prevents paracellular, non-specific entry of the iron-containing transferrin into the brain \[[@B17-pharmaceuticals-12-00120]\]. Rather, the brain capillary endothelium regulates iron transport into the brain via the expression of transferrin receptors \[[@B9-pharmaceuticals-12-00120],[@B13-pharmaceuticals-12-00120],[@B17-pharmaceuticals-12-00120]\]. Iron-transferrin attaches to the transferrin receptor, which results in the formation of endocytic vesicles. Recent studies have also shown that the transferrin receptor of the BBB can bind and take up circulating ferritin \[[@B18-pharmaceuticals-12-00120],[@B19-pharmaceuticals-12-00120],[@B20-pharmaceuticals-12-00120],[@B21-pharmaceuticals-12-00120]\]. These vesicles are slightly acidic, and the lower pH reduces the binding affinity of iron to transferrin, which loosens their binding. The iron, present on its ferric form, is reduced to ferrous iron, which can be transported out of the endosome and into the cytosol by divalent metal transporter 1 (DMT1) \[[@B22-pharmaceuticals-12-00120]\]. The release of iron from transferrin within the endosome causes the iron-free apo-transferrin to detach from the transferrin receptor, which allows unbound apo-transferrin to recycle to the luminal surface \[[@B17-pharmaceuticals-12-00120]\].

Unbound ferrous iron is a potent pro-oxidative molecule that needs immediate oxidation \[[@B23-pharmaceuticals-12-00120],[@B24-pharmaceuticals-12-00120]\]. Consequently, ferrous iron is either oxidized within the cytosol by ferrous oxidases, e.g., ceruloplasmin, or gets transported into the brain's extracellular space via the efflux transporter ferroportin, while undergoing oxidation during passage of the cellular membrane \[[@B23-pharmaceuticals-12-00120]\]. The iron transported across the brain endothelium accordingly occurs in a non-transferrin bound iron form and thereby is a candidate for binding to transferrin present within the brain extracellular space \[[@B17-pharmaceuticals-12-00120]\].

Iron in the cytosol participates in essential metabolic processes, e.g., participation in mitochondrial respiration via incorporation mitochondrial enzymes. Many cell types of the body also store residual iron as ferritin-iron, as ferritin also has pro-oxidant activity and is capable of oxidizing ferrous iron to store around 4500 iron atoms \[[@B25-pharmaceuticals-12-00120],[@B26-pharmaceuticals-12-00120]\]. Of note, however, is that brain capillary endothelial cells hardly express ferritin, except for during development \[[@B27-pharmaceuticals-12-00120]\], suggesting that virtually all iron present within the brain capillary endothelial cells is immediately directed toward transport across the BBB to ensure its function further inside the brain.

Iron is also transferred to the brain via transfer across choroid plexus epithelial cells that form the blood--cerebrospinal fluid (CSF) barrier \[[@B17-pharmaceuticals-12-00120]\]. Like the endothelial cells forming the BBB, the epithelial cells of the choroid plexus also express transferrin receptors \[[@B24-pharmaceuticals-12-00120]\], but the quantitative relevance of the choroid plexus for iron transport into the brain is of less significance due to their much lower surface than that of brain endothelial cells of the BBB. The choroid plexus nonetheless very likely makes an important contribution to cerebral iron homeostasis, as transferrin of the blood plasma is filtered through the blood--CSF barrier and enters the brain ventricles, while transferrin in parallel is also synthesized and secreted from the choroid plexus to enter the brain ventricles \[[@B24-pharmaceuticals-12-00120]\]. In sum, this suggests that transferrin of the brain ventricle, and likely also elsewhere in the brain's extracellular space, is derived from the choroid plexus. In the extracellular compartment of the brain, transferrin is needed to capture non-transferrin-bound iron transported across the BBB or released from neurons and glia. The need for transferrin in the brain's extracellular space is further underscored by the presence of transferrin receptors on neurons \[[@B28-pharmaceuticals-12-00120]\]. Surprisingly, transferrin receptors and DMT1 are hardly detected on major glial cells like astrocytes, oligodendrocytes, and microglia \[[@B23-pharmaceuticals-12-00120],[@B28-pharmaceuticals-12-00120]\], which suggests that iron enters glial cells as non-transferrin-bound iron, possibly via specific transporters like ZIP14 \[[@B29-pharmaceuticals-12-00120]\].

1.2. Transport of Iron into the Developing and Iron-Deficient Brain {#sec1dot2-pharmaceuticals-12-00120}
-------------------------------------------------------------------

The uptake of iron-containing transferrin at the BBB and blood--CSF barriers and the further transportation of iron into the brain are dramatically upregulated in the developing brain \[[@B30-pharmaceuticals-12-00120],[@B31-pharmaceuticals-12-00120],[@B32-pharmaceuticals-12-00120]\]. The higher iron uptake strongly correlates to a higher expression of transferrin receptors by brain endothelial cells in the developing brain, as evidenced from studies on the rodent brain \[[@B30-pharmaceuticals-12-00120],[@B31-pharmaceuticals-12-00120]\]. The upregulated iron transport is attributable to a generally higher need for iron as the progenitor cells of the brain proliferate and differentiate into their final phenotypes \[[@B15-pharmaceuticals-12-00120],[@B16-pharmaceuticals-12-00120],[@B32-pharmaceuticals-12-00120],[@B33-pharmaceuticals-12-00120]\]. Interestingly, as the cerebral turnover of iron is extremely low and ceases with increasing age, virtually all the iron transported across the brain barriers during development is believed to remain within the brain \[[@B10-pharmaceuticals-12-00120],[@B11-pharmaceuticals-12-00120],[@B12-pharmaceuticals-12-00120]\].

Correspondingly, when the events take place during development, the brain also adapts to conditions with deprivation in iron accessibility by the upregulation of transferrin receptors \[[@B28-pharmaceuticals-12-00120]\]. When cerebral iron deficiency occurs, the brain profoundly increases the internalization of transferrin receptors in the capillary endothelial cells. The brain also increases the expression of transferrin receptors in neurons in iron deficiency, whereas glial cells, even in stages with robust iron deficiency, fail to express transferrin receptors \[[@B28-pharmaceuticals-12-00120]\].

Combining iron deficiency with stages of development produces the maximal demand for the brain to mobilize transferrin receptors, but in this context, it is of note that there seems to be an upper limit for the extent to which the brain can adapt. Supporting this notion, the brain failed to increase the expression of transferrin receptors when iron deficiency was subjected to experimental animals during development \[[@B31-pharmaceuticals-12-00120],[@B34-pharmaceuticals-12-00120]\]. Therefore, the failure to further increase transferrin receptor expression suggests that the developing brain is particularly vulnerable to severe iron deficiency.

1.3. The Significance of Iron for Precursor Cells of the Developing Brain {#sec1dot3-pharmaceuticals-12-00120}
-------------------------------------------------------------------------

The availability of iron for the brains' cells must be adequate to undertake several iron-dependent processes, not only to ensure important functions such as cellular division and differentiation, but also the development of the entire brain \[[@B9-pharmaceuticals-12-00120],[@B11-pharmaceuticals-12-00120],[@B12-pharmaceuticals-12-00120]\], e.g., (i) the complex cellular architecture consisting of neuronal axons ensheathed with myelin synthetized by oligodendrocytes, (ii) the complicated brain--barrier interface supported by astrocytes and pericytes to regulate transport in and out of the brain, and (iii) the establishment of an innate immune system in the brain via the formation of microglia.

The significance of iron for maintaining cellular functions has been covered in former reviews \[[@B11-pharmaceuticals-12-00120],[@B12-pharmaceuticals-12-00120],[@B35-pharmaceuticals-12-00120],[@B36-pharmaceuticals-12-00120],[@B37-pharmaceuticals-12-00120]\]. Iron denotes an essential part as the co-factor of several proteins that can be organized into four groups: Non-enzymatic iron-containing proteins; enzymes that use iron-sulfur as a co-factor; enzymes with an iron-containing heme group; iron-containing enzymes without heme or an iron-containing sulfur group. Together, these four groups of proteins undertake essential iron-dependent cellular events, i.e., electron transfer in the mitochondria, regulation of the expression levels of several genes, regulation of cellular division and differentiation, the binding and transport of oxygen, the synthesis of neurotransmitters (in particular serotonin, norepinephrine, and dopamine), the packaging of neurotransmitters in the axon terminal, the reuptake and degradation of neurotransmitters, and the co-factor function for peroxide- and nitrous oxide-generating enzymes for the functioning of immune cells and the intracellular killing of pathogens \[[@B11-pharmaceuticals-12-00120],[@B12-pharmaceuticals-12-00120],[@B35-pharmaceuticals-12-00120],[@B36-pharmaceuticals-12-00120],[@B37-pharmaceuticals-12-00120]\]. More specifically, for the developing brain, these above-mentioned cellular iron-dependent processes make their contribution to adequately ensure series of important events ranging from early formation of the neuronal tube to later differentiation of neuronal precursor cells into neurons and glial cells. Iron is very important for the formation of the neuronal tube, of which the formation is abrogated during a conditional lack of transferrin receptors \[[@B15-pharmaceuticals-12-00120],[@B16-pharmaceuticals-12-00120]\]. Severe iron deficiency early in life is also expected to impair the forming brain due to the loss of function of the iron-containing enzyme ribonucleotide reductase that is essential for cellular division \[[@B38-pharmaceuticals-12-00120]\]. This leads to the major concern that remains unexploited, which predicts that developmental iron deficiency during early gestation can cause a permanent reduction in the number of neuronal and glial cells in spite of iron being supplied later in life, e.g., by admitting iron to the neonate \[[@B39-pharmaceuticals-12-00120]\]. Concerning glial cells, their formation in the developing brain depends on iron-containing enzymes to ensure cellular division and differentiation. Regarding oligodendrocytes, the lack of iron availability during development is thought to significantly affect their capability to form myelin \[[@B11-pharmaceuticals-12-00120],[@B12-pharmaceuticals-12-00120],[@B40-pharmaceuticals-12-00120]\], and current hypotheses concern whether the formation of myelin is permanently affected, even if the iron supply is restored later in life, hence hinting towards a certain time-window during development where iron availability must be adequate to promote myelination \[[@B41-pharmaceuticals-12-00120]\].

1.4. Translational Models of the Brain Development {#sec1dot4-pharmaceuticals-12-00120}
--------------------------------------------------

The effects of iron deficiency on the brain will likely manifest, with the earlier the impacts taking place representing the worst condition. The gestational ages vary dramatically between mammalian species, which is very important to notify when comparing experimental data on the effects of iron deficiency.

The normal brain development of different mammalian species can be compared (<http://www.translatingtime.org/translate>) \[[@B42-pharmaceuticals-12-00120]\]. Events like neurogenesis and myelination in the brains of rats and mice time wise are almost identical ([Figure 1](#pharmaceuticals-12-00120-f001){ref-type="fig"}), but differences dramatically occur when comparing rodents and humans. [Figure 1](#pharmaceuticals-12-00120-f001){ref-type="fig"} also shows that myelination of the human brain compared to myelination in rats and mice is clearly different regarding both timing and the time period of gestation, i.e., myelination of the human brain takes places around post-conception (PC) day 250, which translates to PC day 30 in the rat. The latter is very important to emphasize, because it shows that opposed to the human brain, myelination takes places after birth in the rodent (around P7), which must be taken into account when designing an experimental study on brain development with the purpose of detecting correlations between species.

1.5. Evidence of Deleterious Effects of Iron Deficiency on the Developing Brain {#sec1dot5-pharmaceuticals-12-00120}
-------------------------------------------------------------------------------

The effects of iron deficiency on the gastro-intestinal tract and hematological system are well-described, with the effects being reversible. In contrast, the developing CNS differs from many organs of the body as the impacts are much more prone to be irreversible, even when iron supplies are restored, because the neurons are post-mitotic from the time of birth. The following paragraphs will outline the studies that have been conducted to delineate the effects of iron deficiency on the developing brain, with an emphasis on whether effects were reversible or irreversible. To facilitate the translational relevance, the different species are reported separately based on changes in neuronal and glial functioning, and probable changes in behavior. The selected studies were identified based on a search strategy using PubMed to identify primary research on experimental animal studies and human studies using the following MESH words: iron deficiency, development, brain, or neuro, which revealed approximately 60 relevant studies on experimental animals and observations of the developing human brain during the most recent two decades.

1.6. Experimental Animals {#sec1dot6-pharmaceuticals-12-00120}
-------------------------

The experimental animal data point towards significant effects on the brain during periods of iron deficiency during both the gestational period and after birth ([Table 1](#pharmaceuticals-12-00120-t001){ref-type="table"}). The data on small rodents like rats and mice clearly show that the most dramatic effects on the brain development occur when iron deficiency is introduced in pregnancy, whereas data from larger animals like the domestic pig and non-human primates show an influence when iron deficiency is introduced to the offspring ([Table 1](#pharmaceuticals-12-00120-t001){ref-type="table"}).

Rodents, especially the laboratory rat, denote the most popular experimental animal for studies of iron deficiency. The gestational period in the rat principally covers the first two trimesters in humans, with the transition between 1st and 2nd trimesters occurring only two days before delivery, whereas the third trimester in the human is reflected in the first weeks after birth in the rat ([Figure 1](#pharmaceuticals-12-00120-f001){ref-type="fig"}).

The latter points towards a significant difference in the possibilities to compare human and rodent studies, as feeding of this early postnatal rodent no longer occurs via the transfer of nutrients across the placenta, but instead relies on a functioning gastrointestinal system of the neonate. The absorption of iron mainly occurs in the proximal duodenum and is regulated by the iron availability of the duodenal enterocytes. These are mainly under regulation of the general iron status in the neonate via signaling via circulatory levels of hepcidin, which is a hormone synthetized and released from the liver in response to inflammatory stimuli and high circulatory levels of iron \[[@B43-pharmaceuticals-12-00120]\]. However, inflammation in the neonate may lead to increased levels of hepcidin, as this will negatively affect iron uptake from the gut \[[@B6-pharmaceuticals-12-00120]\], and hence the rodent as a model of development equal to the third semester in the human fetus represents a model of potential risk. On the other hand, for the study of the effects of iron deficiency during development, the early postnatal rodent represents an accessible model with many possibilities for intervention.

The studies pertained on the developing rodent brain all point towards a deleterious effect of dietary iron deficiency subjected to the mother during pregnancy ([Table 1](#pharmaceuticals-12-00120-t001){ref-type="table"}). The effects range from observations based on a direct comparison with normal fed mothers to reports on permanent effects on the brain of the offspring in spite of iron being admitted even early after birth. The effects on the developing rat brain concern structural, biochemical, and behavioral impairments ([Table 1](#pharmaceuticals-12-00120-t001){ref-type="table"}). Structurally, influences include structural defects in general brain development \[[@B48-pharmaceuticals-12-00120]\], and more specifically, the development of dendritic length and arborization, and effects on the formation of synapses \[[@B44-pharmaceuticals-12-00120],[@B53-pharmaceuticals-12-00120],[@B57-pharmaceuticals-12-00120],[@B58-pharmaceuticals-12-00120]\]. A particular focus in many studies has been the effects of changes in the expression level of genes related to the functioning of synaptic transmission \[[@B55-pharmaceuticals-12-00120],[@B59-pharmaceuticals-12-00120]\], vascularization \[[@B55-pharmaceuticals-12-00120]\], and hormones improving metabolism \[[@B61-pharmaceuticals-12-00120]\]. Studies have also reported on defects in the synthesis of monoaminergic neurotransmitters \[[@B46-pharmaceuticals-12-00120],[@B47-pharmaceuticals-12-00120],[@B57-pharmaceuticals-12-00120]\], and growth factors \[[@B48-pharmaceuticals-12-00120]\]. Additionally, studies have reported on behavioral disturbances \[[@B44-pharmaceuticals-12-00120],[@B49-pharmaceuticals-12-00120],[@B51-pharmaceuticals-12-00120],[@B52-pharmaceuticals-12-00120]\]. A single study has reported on the impaired development of glial cells \[[@B65-pharmaceuticals-12-00120]\] and the impaired formation of myelin has also been reported \[[@B44-pharmaceuticals-12-00120],[@B63-pharmaceuticals-12-00120],[@B65-pharmaceuticals-12-00120]\], suggesting that earlier studies demonstrating that changes in the profiles of fatty acids in phospholipids are present in iron deficiency relate back to the functioning of the developing oligodendrocytes \[[@B11-pharmaceuticals-12-00120],[@B12-pharmaceuticals-12-00120],[@B13-pharmaceuticals-12-00120],[@B40-pharmaceuticals-12-00120]\].

The significance of dietary iron deficiency on the developing mouse has gained less attention than that of the rat. Iron deficiency negatively affects the brain weight, iron content, and formation of oligodendrocytes and their myelination \[[@B66-pharmaceuticals-12-00120],[@B80-pharmaceuticals-12-00120]\]. As previously mentioned, genetic depletion of the transferrin receptor in the mouse results in severe fetal effects and impaired neurotransmitter formation \[[@B15-pharmaceuticals-12-00120],[@B16-pharmaceuticals-12-00120]\]. In the guinea pig, a series of studies have been made on neural transmission in the brain stem, and reportedly deleterious effects of iron deficiency were partly restored by dietary supplementation with polyunsaturated fatty acids, indicating a beneficial effect on otherwise impaired myelination \[[@B72-pharmaceuticals-12-00120],[@B73-pharmaceuticals-12-00120],[@B74-pharmaceuticals-12-00120]\].

Most studies of larger animals have been conducted in postnatal animals, which, for practical reasons, make this approach durable \[[@B8-pharmaceuticals-12-00120]\]. Studies of gestational iron deficiency performed in the domestic pig report on impaired myelination, but without cognitive effects \[[@B72-pharmaceuticals-12-00120]\]. Impaired myelination was also reported in piglets, who were only subjected to postnatal iron deficiency \[[@B75-pharmaceuticals-12-00120]\]. Interestingly, epigenetic regulation is also affected when iron deficiency is present in the piglet brain \[[@B74-pharmaceuticals-12-00120]\]. Another intriguing study using MRI reports on permanent changes in the brain of the domestic pig in spite of the reversal of brain iron with dietary treatment \[[@B73-pharmaceuticals-12-00120]\].

In terms of the non-human primate brain, a single study has reported on cognitive effects following gestational iron deficiency, but the effects were not consistent and were largely dependent on the induced dietary regimen \[[@B79-pharmaceuticals-12-00120]\]. Studies on iron deficiency induced in the offspring have demonstrated that this led to significant changes in nuclear magnetic resonance (NMR)-detectable metabolites and proteomic profiles in CSF, clearly hinting towards impaired cerebral metabolism \[[@B76-pharmaceuticals-12-00120],[@B77-pharmaceuticals-12-00120]\]. Another study has concluded that iron deficiency subjected to the offspring led to behavioral deficits that were compensable, suggesting that the effects of iron deficiency were less deteriorating \[[@B78-pharmaceuticals-12-00120]\].

1.7. The Developing Human Brain {#sec1dot7-pharmaceuticals-12-00120}
-------------------------------

In humans, the brain forms very early, and maternal iron deficiency is likely to impair the developing brain during the entire period of pregnancy. Compiling the studies reporting the negative impact of iron deficiency on the formation of the developing brain in experimental animals, the following factors stand out as being particularly important: The timing and the severity of the iron deficiency regimens. These factors are also very important to keep in mind when considering the impact of iron deficiency or iron deficiency with anaemia in the human brain, as they are likely to be the most determinant concerning whether damage is at risk of being irreversible \[[@B81-pharmaceuticals-12-00120],[@B82-pharmaceuticals-12-00120]\]. The effects of iron deficiency on brain development were suggested to include the genesis of dendrites and synapses, hence clearly addressing the effects of iron deficiency on differentiation during formation of the human brain, and specifically suggesting an impact on particular brain regions such as the cerebral cortex (i.e., frontal cortex, prefrontal-striatal network, auditive cortex), hippocampus, and striatum \[[@B3-pharmaceuticals-12-00120],[@B82-pharmaceuticals-12-00120]\]. Prior studies were clearly limited in access to measurements on brain functioning in real-time and merely relied on correlations between the iron status measured in blood and putative changes in behavior. Infants with low cord-blood s-ferritin and haemoglobin were prone to negative emotions, and they were less alert and difficult to sooth, and in a 5-year follow-up, the children had poorer behaviour and development outcomes, trouble with auditory language skills, and fine motor skills \[[@B82-pharmaceuticals-12-00120],[@B83-pharmaceuticals-12-00120],[@B84-pharmaceuticals-12-00120]\]. A single trial showed that maternal anaemia in pregnancy could be linked to 14% of cases of mental retardation at a 7-year follow-up. It should, however, also be kept in mind that iron deficiency in humans is not likely to be as extreme as can be instituted in experimental animals, and this should indeed be kept in mind when translating data from animal models to hypotheses in human physiology. A valid indicator of the severity in humans is seen when iron deficiency is complicated with anemia. In this situation, the iron transport to the fetus will be prioritized over the maternal iron need unless a certain threshold (ferritin ≈ 14 µg/L) is met \[[@B8-pharmaceuticals-12-00120],[@B83-pharmaceuticals-12-00120]\]. Furthermore, in severe cases of iron deficiency with anemia, fetal erythropoiesis is more highly prioritized than neurodevelopment \[[@B33-pharmaceuticals-12-00120],[@B58-pharmaceuticals-12-00120]\].

The data obtained from several studies in humans all congregate towards the conclusion that there are significant effects on brain development, both pre-and postnatally ([Table 2](#pharmaceuticals-12-00120-t002){ref-type="table"}). Compared to the more extreme situations that invariably relate to the experimental animals, the impairment in iron statuses is not so dramatic in the human brain, and hence also the reported results \[[@B83-pharmaceuticals-12-00120],[@B84-pharmaceuticals-12-00120],[@B85-pharmaceuticals-12-00120],[@B86-pharmaceuticals-12-00120],[@B87-pharmaceuticals-12-00120],[@B88-pharmaceuticals-12-00120],[@B89-pharmaceuticals-12-00120],[@B90-pharmaceuticals-12-00120],[@B91-pharmaceuticals-12-00120],[@B92-pharmaceuticals-12-00120],[@B93-pharmaceuticals-12-00120],[@B94-pharmaceuticals-12-00120],[@B95-pharmaceuticals-12-00120],[@B96-pharmaceuticals-12-00120],[@B97-pharmaceuticals-12-00120],[@B98-pharmaceuticals-12-00120],[@B99-pharmaceuticals-12-00120],[@B100-pharmaceuticals-12-00120],[@B101-pharmaceuticals-12-00120],[@B102-pharmaceuticals-12-00120],[@B103-pharmaceuticals-12-00120],[@B104-pharmaceuticals-12-00120],[@B105-pharmaceuticals-12-00120],[@B106-pharmaceuticals-12-00120]\]. The studies of humans have mainly involved structural analyses on brain growth in real-time \[[@B83-pharmaceuticals-12-00120],[@B84-pharmaceuticals-12-00120],[@B85-pharmaceuticals-12-00120],[@B86-pharmaceuticals-12-00120],[@B87-pharmaceuticals-12-00120],[@B88-pharmaceuticals-12-00120],[@B89-pharmaceuticals-12-00120]\], neurophysiological measurements of basic functions related to myelination and cranial nerve development \[[@B90-pharmaceuticals-12-00120],[@B91-pharmaceuticals-12-00120],[@B92-pharmaceuticals-12-00120],[@B93-pharmaceuticals-12-00120],[@B94-pharmaceuticals-12-00120],[@B95-pharmaceuticals-12-00120],[@B96-pharmaceuticals-12-00120]\], and neuropsychological tests of cognition, memory, and personal traits \[[@B97-pharmaceuticals-12-00120],[@B98-pharmaceuticals-12-00120],[@B99-pharmaceuticals-12-00120],[@B100-pharmaceuticals-12-00120],[@B101-pharmaceuticals-12-00120],[@B102-pharmaceuticals-12-00120],[@B103-pharmaceuticals-12-00120],[@B104-pharmaceuticals-12-00120],[@B105-pharmaceuticals-12-00120],[@B106-pharmaceuticals-12-00120]\].

Concerning the studies on the development of the brain that took morphological approaches, reports indicate that brain volumes, neurogenesis, and iron content are reduced \[[@B83-pharmaceuticals-12-00120],[@B84-pharmaceuticals-12-00120],[@B85-pharmaceuticals-12-00120]\]. This also led to permanent defects in neuronal connectivity years after developmental iron deficiency was recovered \[[@B91-pharmaceuticals-12-00120]\], which was further associated with a higher risk for psychiatric disorders \[[@B87-pharmaceuticals-12-00120],[@B88-pharmaceuticals-12-00120]\], but not for causing autism \[[@B89-pharmaceuticals-12-00120]\].

Influences of impaired sensory function and neuronal development were also attributed to developmental iron deficiency using auditory brainstem responses (ABR) \[[@B90-pharmaceuticals-12-00120],[@B91-pharmaceuticals-12-00120],[@B92-pharmaceuticals-12-00120],[@B93-pharmaceuticals-12-00120]\]. However, at least one study brought the reliability of this measure into question \[[@B90-pharmaceuticals-12-00120]\] and hinted that changes in ABR can have other explanation. Other studies taking a neurophysiological approach showed impairment in the visual input and general brain activity \[[@B94-pharmaceuticals-12-00120],[@B95-pharmaceuticals-12-00120],[@B96-pharmaceuticals-12-00120]\], suggesting that, e.g., dopaminergic neurotransmission is affected \[[@B95-pharmaceuticals-12-00120]\].

Examining higher functional tasks, the impact on structures and their function in the forebrain have been reported in many studies of the hippocampus (various memory tasks) \[[@B97-pharmaceuticals-12-00120],[@B98-pharmaceuticals-12-00120],[@B99-pharmaceuticals-12-00120]\] and cerebral cortex (social behavior, cognition, association with ADHD) \[[@B100-pharmaceuticals-12-00120],[@B102-pharmaceuticals-12-00120],[@B103-pharmaceuticals-12-00120],[@B105-pharmaceuticals-12-00120],[@B106-pharmaceuticals-12-00120]\]. Conversely, behavior was reportedly not affected in two other studies \[[@B101-pharmaceuticals-12-00120],[@B102-pharmaceuticals-12-00120]\], which suggest that effects on the developing brain could be subtle unless dramatic maternal iron deficiency occurs.

2. Conclusions {#sec2-pharmaceuticals-12-00120}
==============

The human brain develops throughout the gestational period, ranging from the formation and proliferation of neuroprogenitor cells, to their later migration, and later differentiation into fully developed neurons and glial cells. Severe iron deficiency can negatively impact cell division, neurotic outgrowth and formation of the neuronal network, and myelination in glial cells. Experimental studies in animals, especially the laboratory rat, clearly support that these cellular events can be impacted by developmental iron deficiency. In the human brain, where events in the third semester are reflected in the initial postnatal weeks, reports also point towards the negative impact of iron deficiency during development. The quality of the identified studies reported here, including the number of involved subjects, appears valid, but some limitations subtract the possibilities for overall conclusions. The translational value of the result of the experimental animal is high, but more data obtained in higher animals with a longer gestation than the rodent brain would be appreciated. Concerning the human data, a certain shortage in the number of available studies prevails and more studies monitoring the cerebral function postnatally are needed. With respect to the validity of the results, it must also be emphasized that publication bias may exist towards the demonstration of effects of iron deficiency on brain development. This would leave out negative results that may remain unpublished, and this may play an important role as scientific results on the developing human brain are rather scarce. Investigations on the brain in the gestational period are obviously very complicated, so research on biomarkers from the umbilical cord or chorion villus biopsy would be highly appreciated.

In terms of the prevention of iron deficiency, strategies have not yet been developed to specifically address the developing brain. Supplementation with oral or parenteral iron is possible in pregnancy and postnatally \[[@B2-pharmaceuticals-12-00120]\], and strategies to halt iron deficiency anemia will likely also improve cerebral iron deficiency as the brain is able to extract iron from the blood due to the expression of transferrin receptors on brain capillaries \[[@B39-pharmaceuticals-12-00120]\]. Parenteral iron supplementation is being assayed in pregnant women and women with post-partum hemorrhage to generally improve their iron status \[[@B2-pharmaceuticals-12-00120],[@B4-pharmaceuticals-12-00120],[@B107-pharmaceuticals-12-00120],[@B108-pharmaceuticals-12-00120]\], and this will likely also improve the cerebral iron status.
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![Comparison of the developmental ages of the human, rat, mouse, and guinea pig with respect to myelination of the entire brain. C = day of conception. Psuffixnr = postnatal day. PCd = post-conception day. P = partus. GA = human gestation week corresponding to PCd. trim. = Trimester.](pharmaceuticals-12-00120-g001){#pharmaceuticals-12-00120-f001}

pharmaceuticals-12-00120-t001_Table 1

###### 

Studies in experimental animals showing cerebral effects of iron deficiency (ID) subjected to pregnant females or their offspring. References are listed chronologically after species rather than after specific topics, as the many studies addressed more than a single objective. Most data were obtained from studies on rats. Abbreviations: ABR, auditory brainstem responses; DPOAE, distortion product of otoacoustic emissions; IHC, immunohistochemistry; PUFA, long-chain polyunsaturated fatty acids.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Species                 Study Design                            Method                   Offspring Age                                                                                                                                     Conclusion                                                                  Reference
  ----------------------- --------------------------------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------
  Rat                     ID before conception + Gestational ID   Electrophysiological\    P15--P30, P65                                                                                                                                     Late term effects on synapses in hippocampus\                               \[[@B44-pharmaceuticals-12-00120]\]
                                                                  recordings                                                                                                                                                                 in spite of cerebral iron repletion                                         

  ID before conception    Behavior                                P10--Adult               Some persistent effects in spite of iron repletion                                                                                                \[[@B45-pharmaceuticals-12-00120]\]                                         

  ID before conception\   Brain iron\                             P35                      Behavioral impairments related to persistent\                                                                                                     \[[@B46-pharmaceuticals-12-00120]\]                                         
  + Gestational ID        Neurotransmitters                                                loss in dopamine in spite of brain iron reversal                                                                                                                                                                              

  Gestational ID\         mRNA                                    P6--P21                  ID from E15 leads to alteration in tyrosine\                                                                                                      \[[@B47-pharmaceuticals-12-00120]\]                                         
  + Lactational ID                                                                         hydroxylase and reversibility in behavior                                                                                                                                                                                     

  Gestational ID\         mRNA, proteins\                         P7--P15; P30             Lower BDNF, impaired neuronal differentiation                                                                                                     \[[@B48-pharmaceuticals-12-00120]\]                                         
  + Lactational ID        morphology                                                                                                                                                                                                                                                                                     

  ID before conception\   Behavior                                Adult                    Detrimental effects of behavioral tasks, sex dependency                                                                                           \[[@B49-pharmaceuticals-12-00120]\]                                         
  + Gestational ID                                                                                                                                                                                                                                                                                                       

  Gestational ID          Myelination                             P25                      Impaired myelination with correlation to impairment                                                                                               \[[@B50-pharmaceuticals-12-00120]\]                                         

  Gestational ID          mRNA, proteins                          P32--P69                 Effect of behavior, no effects on motor skills in hippocampus                                                                                     \[[@B51-pharmaceuticals-12-00120]\]                                         

  Gestational ID\         Behavior                                P65                      Permanent changes in behavioral tasks                                                                                                             \[[@B52-pharmaceuticals-12-00120]\]                                         
  + Lactational ID                                                                                                                                                                                                                                                                                                       

  Gestational ID\         mRNA\                                   P7--P65                  Permanent changes in mRNA of neuronal markers and dendritic branching in spite of postnatal reversal to normal diet                               \[[@B53-pharmaceuticals-12-00120]\]                                         
  + Lactational ID        morphology                                                                                                                                                                                                                                                                                     

  Gestational ID          mRNA, T3, T4                            P12                      Marked reduction in T3, T4                                                                                                                        \[[@B54-pharmaceuticals-12-00120]\]                                         

  Rat                     ID before conception\                   ABR, DPOAE               P0--P45                                                                                                                                           First trimester displays profound changes in auditory brain stem response   \[[@B55-pharmaceuticals-12-00120]\]
                          + Gestational ID                                                                                                                                                                                                                                                                               

  Gestational ID\         MRI, NMR                                P7--56                   Restoration of brain iron, permanent size reduction in hippocampus and neurochemical hall-markers in spite of postnatal reversal to normal diet   \[[@B56-pharmaceuticals-12-00120]\]                                         
  + Lactational ID                                                                                                                                                                                                                                                                                                       

  Gestational ID          mRNA                                    P7--P56                  Impaired formation of neuronal network and impaired neuronal plasticity in spite of postnatal reversal to normal diet                             \[[@B57-pharmaceuticals-12-00120]\]                                         

  Gestational ID          Morphology                              P21--P40                 25% reduction in dendritic length\                                                                                                                \[[@B58-pharmaceuticals-12-00120]\]                                         
                                                                                           20% reduction in axonal diameter                                                                                                                                                                                              

  ID before conception\   ABR                                     P40                      Increased ABR latencies in ID depending on stage of ID                                                                                            \[[@B59-pharmaceuticals-12-00120]\]                                         
  + Gestational ID                                                                                                                                                                                                                                                                                                       

  Gestational ID\         mRNA                                    P10--P15                 Elevated angiogenic/vasculogenic signaling with increased blood vessel complexity                                                                 \[[@B60-pharmaceuticals-12-00120]\]                                         
  + Lactational ID                                                                                                                                                                                                                                                                                                       

  ID before conception\   mRNA, T3, T4                            E13--P10                 Marked reduction in T3, T4\                                                                                                                       \[[@B61-pharmaceuticals-12-00120]\]                                         
  + gestational ID                                                                         Lowering of thyroid hormone responsive genes                                                                                                                                                                                  

  Embryonic brain         mRNA                                    Not available\           DFO-induced ID lowers expression of series of markers of dendritic and synaptic development, and mitochondrial function                           \[[@B62-pharmaceuticals-12-00120]\]                                         
                                                                  (Cultures at E16)                                                                                                                                                                                                                                      

  Gestational ID          Tactile stimuli                         P1--P32                  Tactile stimuli reverse defect myelination and alteration in oligodendrocytes and microglia, but not astrocytes                                   \[[@B63-pharmaceuticals-12-00120]\]                                         

  Rat                     Gestational ID                          Pro/anti-oxidant         P0--P70                                                                                                                                           Age- and iron-dependent levels of oxidative stress profiling                \[[@B64-pharmaceuticals-12-00120]\]

  Gestational ID          mRNA, IHC                               P21, P35                 Defect myelination, alteration in glial cells                                                                                                     \[[@B65-pharmaceuticals-12-00120]\]                                         

  Mouse                   Gestational ID\                         Hematology               E17--E18                                                                                                                                          Effect of brain weight, lower brain iron                                    \[[@B66-pharmaceuticals-12-00120]\]
                          Brain iron                                                                                                                                                                                                                                                                                     

  ID in offspring         Brain iron                              Adult                    Correction of cerebral ID with parenteral iron                                                                                                    \[[@B67-pharmaceuticals-12-00120]\]                                         

  Guinea Pig              Gestational ID\                         ABR                      P9--P24                                                                                                                                           Effect of ABR in ID\                                                        \[[@B68-pharmaceuticals-12-00120]\]
                          + Lactational ID                                                                                                                                                                                                   Part restoration with PUFA treatment                                        

  Gestational ID\         ABR                                     P24                      Effect of ABR in ID                                                                                                                               \[[@B69-pharmaceuticals-12-00120],[@B70-pharmaceuticals-12-00120]\]         
  + Lactational ID                                                                                                                                                                                                                                                                                                       

  Domestic Pig            Gestational ID\                         Cognitive tasks          0--4 weeks after birth                                                                                                                            No cognitive deficits                                                       \[[@B71-pharmaceuticals-12-00120]\]
                          + Lactational ID                                                                                                                                                                                                                                                                               

  ID in offspring         MRI                                     0--6 weeks after birth   Cerebral ID, alteration in brain tissue\                                                                                                          \[[@B72-pharmaceuticals-12-00120]\]                                         
                                                                                           composition persists in spite of iron repletion                                                                                                                                                                               

  Lactational ID          RNA analysis                            4 weeks after birth      Change in hippocampal DNA methylation and gene regulation                                                                                         \[[@B73-pharmaceuticals-12-00120]\]                                         

  Gestational ID          MRI, IHC                                PD 2--30                 ID after PD 14 detriments white matter                                                                                                            \[[@B74-pharmaceuticals-12-00120]\]                                         

  Monkey                  ID in offspring                         1H NMR                   Infancy                                                                                                                                           Change in metabolomic profile in CSF                                        \[[@B75-pharmaceuticals-12-00120]\]

  ID in offspring         Proteomic                               Infancy                  Persistent change in proteomic profile in CSF                                                                                                     \[[@B76-pharmaceuticals-12-00120]\]                                         

  ID in offspring         1H NMR                                  Infancy                  Metabolomic profile in CSF predicts effects of ID on brain iron metabolism                                                                        \[[@B77-pharmaceuticals-12-00120]\]                                         

  ID in offspring         Cognitive tasks                         Infancy                  Only initial cognitive + behavioral deficits                                                                                                      \[[@B78-pharmaceuticals-12-00120]\]                                         

  Gestational ID\         Cognitive tasks                         Infancy                  Cognitive and emotional effects present, but vary with protocol                                                                                   \[[@B79-pharmaceuticals-12-00120]\]                                         
  + Lactational ID                                                                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

pharmaceuticals-12-00120-t002_Table 2

###### 

Studies of humans showing cerebral effects of iron deficiency (ID) or iron deficiency with anemia (IDA) subjected to pregnant females or their offspring. References are listed after specific topics. Abbreviations: ABR, auditory brainstem responses; LBW, low birth weight; No. F/O, numbers of patients (females/offspring); PND, postnatal day; VEP, visually evoked potentials.

  Study Objective                Evidence of ID       Infant Age          No. F/O   Conclusion                                                                                                                          Reference
  ------------------------------ -------------------- ------------------- --------- ----------------------------------------------------------------------------------------------------------------------------------- --------------------------------------
  Fetal brain development                                                                                                                                                                                               
  Normal development             Maternal IDA         PND 3--5 days       /70       Maternal IDA adversely affects l hippocampal morphogenesis and fetal production of BDNF                                             \[[@B83-pharmaceuticals-12-00120]\]
  Normal development             Maternal IDA         18 months           331/      Maternal ID at 34 weeks associated with lower motor scores                                                                          \[[@B84-pharmaceuticals-12-00120]\]
  Normal development             Normal iron status   7--11 years         /39       MRI iron content in basal ganglia influences spatial intelligence                                                                   \[[@B85-pharmaceuticals-12-00120]\]
  Brain connectivity             Infant IDA           Mean 21.5 years     /31       Different patterns of functional connectivity between former IDA and control young adults                                           \[[@B86-pharmaceuticals-12-00120]\]
  Risk of schizophrenia          Maternal IDA         Prospective study   /6872     Maternal ID as risk factor for schizophrenia in offspring                                                                           \[[@B87-pharmaceuticals-12-00120]\]
  Cerebral functions             IDA in adults        Adult               /2957     IDA associated with increases in psychiatric disorders                                                                              \[[@B88-pharmaceuticals-12-00120]\]
  Autism                         Infant IDA           2--7 years          /102      No evidence between IDA and autism                                                                                                  \[[@B89-pharmaceuticals-12-00120]\]
  **Basic cerebral functions**                                                                                                                                                                                          
  ABR                            LBW                  PND 42--6 months    /285      Iron supplements did not improve ABR, but ABR was discarded as measure of impairment in ID                                          \[[@B90-pharmaceuticals-12-00120]\]
  ABR                            Maternal IDA         PND 2, 3 months               ABR closely related to severity of maternal and neonatal iron status                                                                \[[@B91-pharmaceuticals-12-00120]\]
  ABR                            Infant IDA           6--24 months                  Prolonged latencies in ABR traces in IDA                                                                                            \[[@B92-pharmaceuticals-12-00120]\]
  ABR                            Infant IDA           \<48 h              /90       Latent iron deficiency associated with abnormal ABR                                                                                 \[[@B93-pharmaceuticals-12-00120]\]
  VEP                            Infant IDA           6--24 months        /50       Negative correlation between severity of IDA and VEP latencies                                                                      \[[@B94-pharmaceuticals-12-00120]\]
  Eye-blinking rates             Infant IDA           9--10 months        61        Increased eye-blink rats consistent with low dopamine function in IDA                                                               \[[@B95-pharmaceuticals-12-00120]\]
  EEG recordings                 Infant IDA           0, 9 months         /80       ID associated with EEG asymmetry                                                                                                    \[[@B96-pharmaceuticals-12-00120]\]
  **Memory**                                                                                                                                                                                                            
  Memory                         Infant IDA           8--10 years         /201      Iron supplementation substantially restores cognitive capabilities                                                                  \[[@B97-pharmaceuticals-12-00120]\]
  Execution, memory              Infant IDA           19 years            /114      Chronic impairment of functions related to frontostriatal-connections (executive functions), and hippocampus (recognition memory)   \[[@B98-pharmaceuticals-12-00120]\]
  Recognition memory             Infant IDA           6--18 months        /209      Sustained effects on memory in 10-year follow-up in spite of oral supplement in early life                                          \[[@B99-pharmaceuticals-12-00120]\]
  Higher cerebral functions                                                                                                                                                                                             
  Social-emotional behavior      Infant IDA           9--10 years         /77       Social-emotional behavior associated with ID                                                                                        \[[@B100-pharmaceuticals-12-00120]\]
  Behavior                       Normal               6--8 years          /264      Fe supplementation in pregnancy without consistent effect on behavior                                                               \[[@B101-pharmaceuticals-12-00120]\]
  Cognition                      Infant IDA           1--3 years          /3        Improvement in cognition once iron stores were restored                                                                             \[[@B102-pharmaceuticals-12-00120]\]
  Cognition                      Infant IDA           Mean age 12.0                 Reduced cognitive performance                                                                                                       \[[@B103-pharmaceuticals-12-00120]\]
  Cognition                      Infant IDA           12 months           828/828   No effect of IDA on cognition or motor development                                                                                  \[[@B104-pharmaceuticals-12-00120]\]
  ADHD symptomology, IQ          Infant IDA           2.5--5 years        /123      Effects of early deprivation and ID on ADHD symptoms and IQ years after adoption                                                    \[[@B105-pharmaceuticals-12-00120]\]
  ADHD symptomology              Infant IDA           Mean age 11.0                 IDA associated with ADHD                                                                                                            \[[@B106-pharmaceuticals-12-00120]\]
